BAJAJ BROKING
Marksans Pharma reported ₹709 crore in consolidated revenue and ₹91 crore in net profit for Q4 FY25. For the full year, revenue stood at ₹2,623 crore, with net profit growing 21.5% YoY, driven by robust performance across global markets..
Q4 FY25 Revenue: ₹708.5 crore, up 26.5% YoY
Q4 FY25 PAT: ₹90.7 crore, up 16.9% YoY
FY25 Revenue: ₹2,622.8 crore, up 20.5% YoY
FY25 PAT: ₹382.6 crore, up 21.5% YoY
EBITDA for FY25 stood at ₹528.6 crore; EBITDA margin was 20.2%
EPS for FY25 rose to ₹8.4 from ₹6.9 in FY24
Gross Margin improved by 407 bps YoY to 56.4%
Particulars | Q4 FY25 | Q4 FY24 | YoY Change |
Operating Revenue (₹ crore) | 708.5 | 560.0 | +26.5% |
Gross Profit (₹ crore) | 383.2 | 290.2 | +32.1% |
Gross Margin (%) | 54.1% | 51.8% | +228 bps |
EBITDA (₹ crore) | 125.8 | 109.6 | +14.7% |
EBITDA Margin (%) | 17.8% | 19.6% | -183 bps |
PAT (₹ crore) | 90.7 | 77.6 | +16.9% |
Net Margin (%) | 12.5% | 13.5% | -95 bps |
EPS (₹) | 2.0 | 1.7 | +15.7% |
Segment | Q4 FY25 (₹ Cr) | Q4 FY24 (₹ Cr) | YoY Growth | FY25 (₹ Cr) | FY24 (₹ Cr) | YoY Growth | Share of FY25 Revenue |
US & North America | 328.6 | 245.0 | +34.1% | 1,236.6 | 918.1 | +34.7% | 47.1% |
UK & Europe | 274.1 | 232.8 | +17.7% | 1,029.8 | 943.0 | +9.2% | 39.3% |
Australia & New Zealand | 76.5 | 63.3 | +20.9% | 252.8 | 218.8 | +15.5% | 9.6% |
Rest of World (RoW) | 29.3 | 18.9 | +55.0% | 103.7 | 97.4 | +6.4% | 4.0% |
Total Revenue | 708.5 | 560.0 | +26.5% | 2,622.8 | 2,177.4 | +20.5% | 100% |
Marksans Pharma’s 21.5% rise in FY25 net profit and 20.5% revenue growth align with the broader industry’s focus on US market penetration and operational scalability. Performance across OTC and formulation segments was in line with evolving global demand trends.
“We are pleased to announce another year of robust performance; we have achieved highest ever annual revenues and profits. In FY25, we witnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing INR 2000 Crs in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looking forward, we continue to strengthen our foundation by increasing the capacity and strengthening our product pipeline. We are optimistic about building on this momentum and create more value for our stakeholders in the coming years.”
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading